文献速递前列腺癌

模拟禁食饮食对前列腺癌患者代谢健康的影响:一项前瞻性队列试点实施研究

The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-03-21

这项前瞻性试点研究纳入35例前列腺癌患者,29例完成每3个月一次、每次连续4天的模拟禁食饮食(FMD)周期。完成周期3个月后复查显示体重平均下降3.79 kg(95%CI:-5.61,-1.97,p=0.0002),腹围平均减少4.57 cm(95%CI:-2.27,-6.87,p=0.0003),收缩压和舒张压分别下降9.52 mmHg(95%CI:-16.16,-2.88,p=0.0066)和4.48 mmHg(95%CI:-8.85,-0.43,p=0.0316)。FMD周期在该小队列中安全引入,观察到毒性很少或没有,总体依从性83%。

要点

  • 29/35例前列腺癌患者完成每3个月一次、连续4天的FMD周期,总体依从性83%。
  • 完成FMD周期3个月后体重平均下降3.79 kg、腹围平均减少4.57 cm。
  • 收缩压平均下降9.52 mmHg、舒张压平均下降4.48 mmHg,基线收缩压>130 mmHg者降幅更大。

核心结论

  • FMD周期在该小队列前列腺癌患者中安全引入,观察到毒性很少或没有,总体依从性83%。
  • 代谢变量分析显示体重、腹围和血压总体下降。
  • 需要更大规模、聚焦代谢危险因素、前列腺癌生活质量和无进展生存期的临床试验来评估FMD对前列腺癌患者的作用。

研究设计与样本

  • 前瞻性试点实施研究,纳入35例前列腺癌患者,29例完成每3个月一次、连续4天的包装FMD周期(ClinicalTrials.gov标识号NCT04292041)。
  • FMD为低热量、低糖、低蛋白但高不饱和脂肪的4天饮食方案。
  • 比较受试者基线体重、腹围、血压和选定实验室结果与完成FMD周期3个月后的相同测量。

主要发现

  • 体重平均下降3.79 kg(95%CI:-5.61,-1.97,p=0.0002)。
  • 腹围平均减少4.57 cm(95%CI:-2.27,-6.87,p=0.0003)。
  • 收缩压平均下降9.52 mmHg(95%CI:-16.16,-2.88,p=0.0066),舒张压平均下降4.48 mmHg(95%CI:-8.85,-0.43,p=0.0316)。
  • 亚组分析显示FMD对「高危」患者比危险因素值正常者影响更相关,例如基线收缩压>130 mmHg者血压下降-16.04 mmHg(p=0.0001),大于基线收缩压<130 mmHg者的-0.78 mmHg(p=0.89)。

临床怎么用

  • 作者指出需要更大规模、聚焦代谢危险因素、前列腺癌生活质量和无进展生存期的临床试验来评估FMD对前列腺癌患者的作用。

局限性

  • 原文指出该队列样本量小(该小队列)。
  • 原文指出需要更大规模临床试验来评估FMD对前列腺癌患者的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This pilot prospective study investigated the effect of a periodic fasting mimicking diet (FMD) on metabolic health factors in patients with Prostate Cancer (PC). There is a well-documented association between PC and metabolic health. Impaired metabolic health is a significant risk factor for the development of PC, and a metabolic syndrome can be induced by hormonal therapies commonly required for its management. (ClinicalTrials.gov Identifier: NCT04292041). METHODS: We introduced a periodic 4-day FMD -low in calories, sugars, and proteins but high in unsaturated fats -to a cohort of PC patients and features of metabolic syndrome. 29/35 patients completed 3-monthly cycles of the 4-consecutive day packaged FMD. We compared the subjects' baseline weight, abdominal circumference (AC), blood pressure (BP) and selected laboratory results to the same measurements 3-months after completing the FMD cycles. RESULTS: Several important metabolic factors showed improvements post-intervention. On average patients' weights dropped by 3.79 kg (95% CI: -5.61, -1.97, p = 0.0002). AC was reduced on average by 4.57 cm, (95% CI: -2.27, -6.87, p = 0.0003). There was also a decrease in systolic and diastolic BP by 9.52 mmHg (95% CI: -16.16, -2.88, p = 0.0066) and 4.48 mmHg (95% CI: -8.85, -0.43, p = 0.0316) respectively. A sub-analysis indicates that FMD had more relevant effects in 'at-risk' patients than those with normal values of risk factors for metabolic syndrome. For example, subjects with baseline levels of systolic BP > 130 mmHg experienced a greater reduction in BP(-16.04 mmHg, p = 0.0001) than those with baseline systolic BP < 130 mmHg (-0.78 mmHg, p = 0.89). CONCLUSIONS: The FMD cycles were safely introduced to this small cohort of PC patients with little or no observed toxicity, and a high overall compliance of 83%. Analysis of the metabolic variables showed an overall decrease in weight, AC, and BP. Larger clinical trials focused on metabolic risk factors, PC quality of life and progression free survival are needed to assess the effect of the FMD on prostate cancer patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Fay-Watt V, O'Connor S, Roshan D, et al. The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study. Prostate Cancer Prostatic Dis. 2022. PMID: 35314788. doi:10.1038/s41391-022-00528-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。